KONVI
27.6.2024 09:01:30 CEST | Business Wire | Press release
Konvi, Europe’s leading luxury assets fractional investment platform, has announced the launch of a once-in-a-lifetime opportunity to invest in an exclusive Birkin bag designed by Alec Monopoly. This is a particularly exciting investment as it combines a piece of art by a prestigious artist with one of the best investment vehicles in the world – the Birkin bag – and the firm expects a high degree of interest from investors.
The value of a Birkin bag increases immediately upon leaving the store, leading many to say it’s a better investment than gold. Having never fluctuated downwards in value, Birkins are highly lucrative investments that consistently outperform the S&P 500 and boast double-digit annual returns.
Alec Monopoly rose to fame through his bright-coloured graffiti art and paintings which explore the themes of capitalism and luxury lifestyles. Birkin bags designed by Monopoly retail between an astounding $11,900 and $300,000. The famous handbags have also been sported by celebrities, including Khloe Kardashian, who owns a $25,000 piece painted by the artist.
Luxury assets are much more than a popular accessory, as they provide strong investment opportunities. The fact that returns on luxury items are negatively correlated with those on equities, bonds, and other collectible investments, makes them a great addition to an investment portfolio to ensure strong diversification.
Through Konvi’s app, investors can buy fractional shares of the luxury Birkin bag starting from €250 with immediate effect. Konvi buys and insures the asset and then sells it at the highest price, returning money to the asset's co-owners. This model enables users to access an extremely rare investment that would usually require significant capital and a broad network of collectors and auction houses to invest in.
Eran Peer, Co-Founder and CEO, commented: “Launching this exclusive luxury Alec Monopoly Birkin bag investment opportunity for Konvi users is central to our goal of bringing previously inaccessible luxury investment opportunities to a broader range of people. This offering means people can own a share in a bag adorned by some of the biggest celebrities on the planet, including the Kardashians, and reap the investment rewards. We’re excited to be bringing such a high-performing asset to our platform and look forward to launching similar investment opportunities in the near future.”
Investing in luxury assets such as art, fine wines, whiskeys, watches and vintage cars has long been inaccessible to the majority of people. High up-front costs, low availability and opaque, private markets with high fees mean historically only the most sophisticated investors and wealthy individuals could capitalise on these opportunities.
Konvi is the first Pan-European investment platform that enables retail investors to diversify their portfolios by fractionally investing in luxury assets. By collaborating with industry experts with strong track records, Konvi ensures that investment opportunities on its platform are carefully curated and accessible to everyone. Konvi also recently launched its latest Banksy art investment with one of the leading Banksy art piece curators, TGB Contemporary.
Visit Konvi’s website to find out how you can invest in this Alec Monopoly Birkin bag: https://konvi.app/en_GB/
About Konvi
Konvi is a pioneering online platform that democratises access to alternative investments, including hand-curated art, fine wine, classic cars, and more. With a user-friendly interface and innovative strategies, Konvi empowers individuals to build diversified portfolios and achieve their financial goals starting from an investment of €250.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627487145/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
